Seattle Genetics (NASDAQ: SGEN) declined Thursday after ASH abstracts were released. Analyst Adnan Butt of RBC called Bristol-Myers Squibb's (NYSE ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE